Development of an optimized multimarker strategy for early risk assessment of patients with acute coronary syndromes

Clinica Chimica Acta

Volumn 393, Issue 2, 2008, Pages 103-109

  Möckel, Martin ^a   Danne, Oliver ^a   Müller, Reinhold ^b   Vollert, Jörn O ^a   Müller, Christian ^a   Lueders, Christian ^a   Störk, Thomas ^c   Frei, Ulrich ^a   Koenig, Wolfgang ^d   Dietz, Rainer ^a   Jaffe, Allan S ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b JAMES COOK UNIVERSITY   (Australia)

^c OLGAHOSPITAL   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e MAYO CLINIC   (United States)

Author keywords

Acute coronary syndrome; Choline; Classification and regression trees; Early risk stratification; Emergency department; Multi marker approach; NT proBNP

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLINE; D DIMER; PLACENTAL GROWTH FACTOR; TROPONIN I;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANALYTIC METHOD; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; EMERGENCY CARE; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

ANGINA;

EID: 44449125798     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.03.022     Document Type: Article

References (44)

1. Kentsch M., Rodemerk U., Gitt A.K., et al. Angina intensity is not different in diabetic and non-diabetic patients with acute myocardial infarction. Z Kardiol 92 (2003) 817-824
2. Heidenreich P.A., Alloggiamento T., Melsop K., McDonald K.M., Go A.S., and Hlatky M.A. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 38 (2001) 478-485
3. Apple F.S., Wu A.H.B., Mair J., et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 51 (2005) 810-824
4. Apple F.S., Pearce L.A., Chung A., Ler R., and Murakami M.M. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 53 (2007) 874-881
5. Lindahl B., Lindback J., Jernberg T., et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a fragmin and fast revascularisation during instability in coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol 45 (2005) 533-541
6. Derhaschnig U., Laggner A.N., Roggla M., et al. Evaluation of coagulation markers for early diagnosis of acute coronary syndromes in the emergency room. Clin Chem 48 (2002) 1924-1930
7. Danne O., Mockel M., Lueders C., et al. Prognostic implications of elevated whole blood choline concentrations in acute coronary syndromes. Am J Cardiol 91 (2003) 1060-1067
8. Oei H.H., van der Meer I.M., Hofman A., et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam study. Circulation 111 (2005) 570-575
9. Packard C.J., O'Reilly D.S.J., Caslake M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med 343 (2000) 1148-1155
10. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. Circulation 109 (2004) 837-842
11. Khuseyinova N., Imhof A., Rothenbacher D., et al. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis 182 (2005) 181-188
12. Brilakis E.S., McConnell J.P., Lennon R.J., Elesber A.A., Meyer J.G., and Berger P.B. Association of lipoprotein-associated phospholipase A2 concentrations with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 26 (2005) 137-144
13. Heeschen C., Dimmeler S., Fichtlscherer S., et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA 291 (2004) 435-441
14. Hamm C.W. Leitlinien: Akutes Koronarsyndrom (ACS). Z Kardiol 93 (2004) 72-90
15. Hamm C.W. Leitlinien: Akutes Koronarsyndrom (ACS). Z Kardiol 93 (2004) 324-341
16. Antman E., Bassand J.P., Klein W., et al. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction: the Joint European Society of Cardiology/ American College of Cardiology Committee. J Am Coll Cardiol 36 (2000) 959-969
17. Panteghini M., Pagani F., Yeo K.T., et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem 50 (2004) 327-332
18. Christenson R.H., Cervelli D.R., Bauer R.S., and Gordon M. Stratus(R) CS cardiac troponin I method: performance characteristics including imprecision at low concentrations. Clin Biochem 37 (2004) 679-683
19. Prontera C., Emdin M., Zucchelli G.C., Ripoli A., Passino C., and Clerico A. Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clin Chem Lab Med 42 (2004) 37-44
20. Crichton N.J., Hinde J.P., and Marchini J. Models for diagnosing chest pain: is CART helpful?. Stat Med 16 (1997) 717-727
21. Kastrati A., Schomig A., Elezi S., et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 30 (1997) 1428-1436
22. Breiman L., Friedman J.O.R., and Stone C. Classification and regression Trees (1984), Chapman and Hall
23. Mockel M., Muller R., Vollert J.O., et al. Role of N-terminal Pro-B-Type natriuretic peptide in risk stratification in patients presenting in the emergency room. Clin Chem 51 (2005) 1624-1631
24. Baldus S., Heeschen C., Meinertz T., et al. Myeloperoxidase serum concentrations predict risk in patients with acute coronary syndromes. Circulation 108 (2003) 1440-1445
25. Lenderink T., Heeschen C., Fichtlscherer S., et al. Increased placental growth factor concentrations are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. J Am Coll Cardiol 47 (2006) 307-311
26. Heeschen C., Dimmeler S., Hamm C.W., Fichtlscherer S., Simoons M.L., and Zeiher A.M. Pregnancy-associated plasma protein-A concentrations in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol 45 (2005) 229-237
27. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348 (2003) 1104-1111
28. de Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345 (2001) 1014-1021
29. Omland T., Persson A., Ng L., et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106 (2002) 2913-2918
30. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105 (2002) 1760-1763
31. Mega J.L., Morrow D.A., de Lemos J.A., et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 44 (2004) 335-339
32. Morrow D.A., de Lemos J.A., Blazing M.A., et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 294 (2005) 2866-2871
33. Januzzi J.L., van Kimmenade R., Lainchbury J., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the international collaborative of NT-proBNP study. Eur Heart J 27 (2006) 330-337
34. Jernberg T., Stridsberg M., Venge P., and Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 40 (2002) 437-445
35. Jernberg T., Lindahl B., Siegbahn A., et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol 42 (2003) 1909-1916
36. Danne O., Lueders C., Storm C., Frei U., and Mockel M. Whole blood choline and plasma choline in acute coronary syndromes: prognostic and pathophysiological implications. Clin Chim Acta 383 (2007) 103-109
37. Danne O., Lueders C., Storm C., Frei U., and Mockel M. Whole-blood hypercholinemia and coronary instability and thrombosis. Clin Chem 51 (2005) 1315-1317
38. Blake G.J., Dada N., Fox J.C., Manson J.E., and Ridker P.M. A prospective evaluation of lipoprotein-associated phospholipase A2 concentrations and the risk of future cardiovascular events in women. J Am Coll Cardiol 38 (2001) 1302-1306
39. Caslake M.J., Packard C.J., Suckling K.E., Holmes S.D., Chamberlain P., and Macphee C.H. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150 (2000) 413-419
40. Blankenberg S., Stengel D., Rupprecht H.J., et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res 44 (2003) 1381-1386
41. O'Donoghue M., Morrow D.A., Sabatine M.S., et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 113 (2006) 1745-1752
42. Kruskal J.B., Commerford P.J., Franks J.J., and Kirsch R.E. Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. N Engl J Med 317 (1987) 1361-1365
43. al-Nozha M., Gader A.M., al-Momen A.K., Noah M.S., Jawaid M., and Arafa M. Haemostatic variables in patients with unstable angina. Int J Cardiol 43 (1994) 269-277
44. Lindahl B., Toss H., Siegbahn A., Venge P., Wallentin L., and The FRISC Study Group. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 343 (2000) 1139-1147